Investing
Coherus BioSciences surges on FDA Udenyca delivery system approval
© Reuters. Coherus BioSciences (CHRS) surges on FDA Udenyca delivery system approval
Shares of Coherus BioSciences (CHRS) surged 35% in premarket trading on Wednesday after the company announced the U.S. Food and Drug Administration (FDA) approved its UDENYCA ONBODY product.
UDENYCA ONBODY is the company’s on-body injector (OBI) presentation of UDENCYA, designed for a five-minute injection time. The device features an automatic retractable needle mechanism.
“The on-body injector for UDENYCA is the result of years of significant investment in research and development to bring forward a novel and proprietary device that provides patients with an automatic delivery option for their medication,” said Denny Lanfear, CEO of Coherus.
Paul Reider, Coherus’s chief commercial officer, said: “Our market studies showed a significant demand for a novel on-body pegfilgrastim delivery device tailored to specific patient needs. We expect that UDENYCA ONBODY’s five-minute injection time and innovative retractable needle mechanism will be well received by cancer patients, their caregivers, and doctors.”
Coherus said it conducted extensive market research, revealing a strong demand for the system.
The company’s shares are trading just below the $3 per share mark ahead of Wednesday’s open.
Read the full article here
Zillow: These Are the Top 10 Hottest Housing Markets of 2025
Former Zillow Execs Target $1.3T Market
Automate Applications and Supercharge Your Job Hunt for $39
All the PDF Tools You Need in One Easy-to-Use App
Bank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
5 Things That Could Significantly Impact Your Company in 2025
NFI Group surge after board reshaped with new appointments, chairperson By Investing.com
Microsoft Is About to Begin Job Cuts. Here’s Why.
10 Critical Questions to Ask Your Financial Advisor Now
10 Ways to Make Money As a Graphic Designer
Debt ceiling debate and its effect on the U.S. dollar
Debt ceiling default: Still no deal between parties
Stovall: If the U.S. defaults on its debt, all S&P 500 sectors will likely fall
What China's weaker-than-expected economy could mean for U.S. markets
A ‘Big Short’ investor sees financial disaster brewing in housing markets — again
-
Side Hustles6 days ago5 Things That Could Significantly Impact Your Company in 2025
-
Investing6 days agoNFI Group surge after board reshaped with new appointments, chairperson By Investing.com
-
Side Hustles4 days agoMicrosoft Is About to Begin Job Cuts. Here’s Why.
-
Make Money3 days ago10 Critical Questions to Ask Your Financial Advisor Now
-
Make Money2 days ago10 Ways to Make Money As a Graphic Designer
-
Passive Income5 days ago3 Challenges Entrepreneurs Will Face in 2025
-
Side Hustles5 days agoThe Canadian Media Lawsuit That Could Reshape Tech’s Future
-
Investing4 days agoWhat CMOs Need to Know About AI Adoption in Marketing Teams